Home LiteratureArticle Details
PMID: 18077719 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Autorepression of Epstein-Barr virus nuclear antigen 1 expression by inhibition of pre-mRNA processing.

Journal of virology ·Vol. 82 ·No. 4 ·2008-02-00 ·Pages 1679-87

Yoshioka M, Crum MM, Sample JT

Abstract

Epstein-Barr virus (EBV) latent infection, and its associated oncogenic potential, is dependent on genome maintenance functions of EBV nuclear antigen 1 (EBNA-1), one of six EBNAs expressed from a common promoter (Wp and then Cp) upon infection of naive B cells. Subsequent host-mediated silencing, however, necessitates the expression of EBNA-1 from the EBNA-1-specific promoter Qp to ensure against genome loss during cell division, including EBV-associated malignancy. Here we addressed the mechanism by which EBNA-1 represses Qp through binding downstream of the transcription start site and the role of this autoregulatory function in EBV latency. Our results revealed that EBNA-1 does not inhibit transcription from Qp, as previously predicted, but acts post- or cotranscriptionally to block the processing of primary transcripts. This does not, however, require the RGG motifs responsible for strong but nonspecific RNA binding by EBNA-1. Within isogenic B-cell lines using either Cp/Wp or Qp, EBNA-1 occupancy of Qp is equivalent, suggesting that autoregulation occurs, albeit to different degrees, during full and restricted EBV latency programs. Finally, in cell lines using Cp or Wp for EBNA expression, unprocessed transcripts from Qp are detectable in the absence of corresponding mRNAs, providing further evidence that this novel mechanism of EBNA-1 action functions during latency. This posttranscriptional mechanism of regulation would provide an efficient means to monitor and regulate EBNA-1 expression from Qp, ensuring levels adequate for genome maintenance but, perhaps more importantly, below an immunogenic threshold above which latently infected cells may be at risk for elimination by EBNA-1-specific cytotoxic T cells.

MeSH Terms
Base Sequence Down-Regulation Epstein-Barr Virus Nuclear Antigens/chemistry,genetics,immunology Feedback, Physiological Gene Expression Regulation, Viral Herpesvirus 4, Human/genetics,immunology Humans Molecular Sequence Data Promoter Regions, Genetic Protein Structure, Tertiary RNA Precursors/metabolism RNA Processing, Post-Transcriptional RNA, Messenger/metabolism RNA, Viral/metabolism Transcription, Genetic Virus Latency/genetics
Chemicals
Epstein-Barr Virus Nuclear Antigens RNA Precursors RNA, Messenger RNA, Viral EBV-encoded nuclear antigen 1
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Yoshioka Mikio
Department of Microbiology and Immunology-H107, The Pennsylvania State University College of Medicine, The Milton S. Hershey Medical Center, 500 University Dr., P.O. Box 850, Hershey, PA 17033, USA.
Crum Michelle M
Sample Jeffery T
References (63)
63 references, click to expand
  1. The amino terminus of Epstein-Barr Virus (EBV) nuclear antigen 1 contains AT hooks that facilitate the replication and partitioning of latent EBV genomes by tethering them to cellular chromosomes.
    J Virol. 2004 Nov;78(21):11487-505 PMID: 15479791
  2. Human DNA replication initiation factors, ORC and MCM, associate with oriP of Epstein-Barr virus.
    Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10085-9 PMID: 11517328
  3. Multiple EBNA1-binding sites are required to form an EBNA1-dependent enhancer and to activate a minimal replicative origin within oriP of Epstein-Barr virus.
    J Virol. 1989 Jun;63(6):2657-66 PMID: 2542579
  4. Constitutive activation of Epstein-Barr virus (EBV) nuclear antigen 1 gene transcription by IRF1 and IRF2 during restricted EBV latency.
    Mol Cell Biol. 1997 Feb;17(2):873-86 PMID: 9001242
  5. Chromatin profiling of Epstein-Barr virus latency control region.
    J Virol. 2007 Jun;81(12):6389-401 PMID: 17409162
  6. P32/TAP, a cellular protein that interacts with EBNA-1 of Epstein-Barr virus.
    Virology. 1997 Sep 15;236(1):18-29 PMID: 9299613
  7. Characterization of the Epstein-Barr virus Fp promoter.
    Virology. 1995 Jan 10;206(1):183-95 PMID: 7831773
  8. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells.
    Nature. 1985 Feb 28-Mar 6;313(6005):812-5 PMID: 2983224
  9. Interferon-independent and -induced regulation of Epstein-Barr virus EBNA-1 gene transcription in Burkitt lymphoma.
    J Virol. 1997 Sep;71(9):6887-97 PMID: 9261415
  10. Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells.
    J Virol. 1992 Feb;66(2):706-14 PMID: 1370554
  11. Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus.
    J Virol. 2004 Nov;78(22):12308-19 PMID: 15507618
  12. Mapping genetic elements of Epstein-Barr virus that facilitate extrachromosomal persistence of Epstein-Barr virus-derived plasmids in human cells.
    Mol Cell Biol. 1985 Oct;5(10):2533-42 PMID: 3016506
  13. Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals.
    J Virol. 1999 Dec;73(12):9959-68 PMID: 10559309
  14. Methylation of the Epstein-Barr virus genome in normal lymphocytes.
    Blood. 1997 Dec 1;90(11):4480-4 PMID: 9373258
  15. The Epstein-Barr virus EBNA-1 promoter Qp requires an initiator-like element.
    J Virol. 1997 Jan;71(1):354-61 PMID: 8985357
  16. Expression of EBNA-1 mRNA is regulated by cell cycle during Epstein-Barr virus type I latency.
    J Virol. 1999 Apr;73(4):3154-61 PMID: 10074167
  17. Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes.
    J Exp Med. 2007 Mar 19;204(3):525-32 PMID: 17312009
  18. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
    Cancer Res. 2003 Oct 1;63(19):6144-8 PMID: 14559793
  19. An EBNA-1-dependent enhancer acts from a distance of 10 kilobase pairs to increase expression of the Epstein-Barr virus LMP gene.
    J Virol. 1995 Apr;69(4):2633-6 PMID: 7884916
  20. EBNA-1, the major nuclear antigen of Epstein-Barr virus, resembles 'RGG' RNA binding proteins.
    EMBO J. 1994 Oct 17;13(20):4840-7 PMID: 7957053
  21. Epstein-Barr virus nuclear antigen 1 is a DNA-binding protein with strong RNA-binding activity.
    J Gen Virol. 2004 Oct;85(Pt 10):2755-2765 PMID: 15448336
  22. Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines.
    J Virol. 2006 Nov;80(21):10700-11 PMID: 16920819
  23. Reciprocal regulation of the Epstein-Barr virus BamHI-F promoter by EBNA-1 and an E2F transcription factor.
    Mol Cell Biol. 1994 Nov;14(11):7144-52 PMID: 7935429
  24. The Epstein-Barr virus nuclear protein 1 promoter active in type I latency is autoregulated.
    J Virol. 1992 Aug;66(8):4654-61 PMID: 1321268
  25. Human origin recognition complex binds to the region of the latent origin of DNA replication of Epstein-Barr virus.
    EMBO J. 2001 Aug 15;20(16):4588-602 PMID: 11500385
  26. Sequence-specific DNA binding of the Epstein-Barr virus nuclear antigen (EBNA-1) to clustered sites in the plasmid maintenance region.
    Cell. 1985 Oct;42(3):859-68 PMID: 2996781
  27. IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency.
    Mol Cell Biol. 1997 Oct;17(10):5748-57 PMID: 9315633
  28. Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.
    J Exp Med. 2004 May 17;199(10):1421-31 PMID: 15148340
  29. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease.
    Blood. 1996 Oct 15;88(8):3129-36 PMID: 8874213
  30. Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.
    Mol Cell Biol. 1999 Apr;19(4):3216-23 PMID: 10082588
  31. A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection.
    J Virol. 1989 Jun;63(6):2644-9 PMID: 2542577
  32. Telomeric proteins regulate episomal maintenance of Epstein-Barr virus origin of plasmid replication.
    Mol Cell. 2002 Mar;9(3):493-503 PMID: 11931758
  33. Regulation of the EBNA1 Epstein-Barr virus protein by serine phosphorylation and arginine methylation.
    J Virol. 2006 Jun;80(11):5261-72 PMID: 16699006
  34. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    J Virol. 1992 Dec;66(12):7461-8 PMID: 1331531
  35. The link between mRNA processing and transcription: communication works both ways.
    Exp Cell Res. 2004 May 15;296(1):91-7 PMID: 15120999
  36. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8+ T lymphocytes.
    J Exp Med. 2004 Feb 16;199(4):459-70 PMID: 14769850
  37. Arginine methylation an emerging regulator of protein function.
    Mol Cell. 2005 Apr 29;18(3):263-72 PMID: 15866169
  38. Replication from oriP of Epstein-Barr virus requires human ORC and is inhibited by geminin.
    Cell. 2001 Aug 10;106(3):287-96 PMID: 11509178
  39. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus.
    J Virol. 1997 Mar;71(3):1766-75 PMID: 9032305
  40. EBP2 plays a key role in Epstein-Barr virus mitotic segregation and is regulated by aurora family kinases.
    Mol Cell Biol. 2005 Jun;25(12):4934-45 PMID: 15923612
  41. Transcriptional activation by EBV nuclear antigen 1 is essential for the expression of EBV's transforming genes.
    Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):14188-93 PMID: 16966603
  42. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.
    Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):239-44 PMID: 14688409
  43. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein.
    J Virol. 1996 Jan;70(1):623-7 PMID: 8523583
  44. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.
    Science. 2003 Sep 5;301(5638):1371-4 PMID: 12958359
  45. CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1.
    J Exp Med. 2004 May 17;199(10):1409-20 PMID: 15148339
  46. Interferon regulatory factor-2 is a transcriptional activator in muscle where It regulates expression of vascular cell adhesion molecule-1.
    J Cell Biol. 1998 Mar 9;140(5):1265-76 PMID: 9490737
  47. Contrasting effects of PNA invasion of the chimeric DMMYC gene on transcription of its myc and PVT domains.
    Oncol Res. 1997;9(1):41-51 PMID: 9112259
  48. EBP2, a human protein that interacts with sequences of the Epstein-Barr virus nuclear antigen 1 important for plasmid maintenance.
    J Virol. 1999 Apr;73(4):2587-95 PMID: 10074103
  49. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA 1 gene transcription in group 1 Burkitt's lymphoma cell lines.
    J Virol. 1995 Aug;69(8):5039-47 PMID: 7609074
  50. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.
    Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12616-21 PMID: 9356498
  51. Activation of a cell-cycle-regulated histone gene by the oncogenic transcription factor IRF-2.
    Nature. 1995 Sep 28;377(6547):362-5 PMID: 7566094
  52. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.
    Mol Cell Biol. 1985 Aug;5(8):1822-32 PMID: 3018528
  53. Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites.
    J Virol. 1989 Jan;63(1):101-10 PMID: 2535719
  54. Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs.
    Mol Cell Biol. 1997 Jan;17(1):364-77 PMID: 8972217
  55. trans activation of an Epstein-Barr viral transcriptional enhancer by the Epstein-Barr viral nuclear antigen 1.
    Mol Cell Biol. 1986 Nov;6(11):3838-46 PMID: 3025615
  56. Interferon regulatory factor 1 (IRF-1) and IRF-2 distinctively up-regulate gene expression and production of interleukin-7 in human intestinal epithelial cells.
    Mol Cell Biol. 2004 Jul;24(14):6298-310 PMID: 15226432
  57. Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation.
    J Virol. 2000 Nov;74(22):10468-79 PMID: 11044091
  58. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus.
    J Virol. 1999 Apr;73(4):2974-82 PMID: 10074147
  59. Definition of the sequence requirements for binding of the EBNA-1 protein to its palindromic target sites in Epstein-Barr virus DNA.
    J Virol. 1990 May;64(5):2369-79 PMID: 2157891
  60. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.
    J Gen Virol. 1990 Jul;71 ( Pt 7):1481-95 PMID: 2165133
  61. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.
    Nature. 1995 Jun 22;375(6533):685-8 PMID: 7540727
  62. Physical association between the EBV protein EBNA-1 and P32/TAP/hyaluronectin.
    J Biomed Sci. 1998;5(3):173-9 PMID: 9678487
  63. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2.
    Nat Med. 2002 Oct;8(10):1098-104 PMID: 12219084
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
1098-5514
Published
2008-02-00
Epub
2007-00-12
Pages
1679-87
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC2258721
Subset
IM
Grants
NCI NIH HHS · R01 CA056639 · United States
NCI NIH HHS · CA21765 · United States
NCI NIH HHS · P30 CA021765 · United States
NCI NIH HHS · CA056639 · United States
NCI NIH HHS · CA073544 · United States
NCI NIH HHS · R01 CA073544 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com